Nedocromil


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Allergic conjunctivitis As 2% soln: Instill 1-2 drop into each eye bid, may be increased to 4 times/day, if necessary. Max treatment duration: 12 wk. Vernal keratoconjunctivitis As 2% soln: Instill 1 drop into each eye 4 times/day. Inhalation Chronic asthma As metered-dose inhaler: Initial: 2 actuations 4 times/day, may be reduced to bid, according to patient’s response.
Dosage Details
Inhalation/Respiratory
Chronic asthma
Adult: As metered-dose inhaler (2 mg/dose): Initially, 2 actuations 4 times daily. Dose may be reduced to bid, according to patient’s response.
Child: ≥6 yr Same as adult dose.

Ophthalmic
Vernal keratoconjunctivitis
Adult: As 2% soln: Instill 1 drop into each eye 4 times daily.
Child: ≥6 yr Same as adult dose.

Ophthalmic
Allergic conjunctivitis
Adult: As 2% soln: Instill 1-2 drop into each eye bid, may be increased to 4 times daily, if necessary. Max treatment duration: 12 wk.
Child: ≥6 yr Same as adult dose.
Special Precautions
Not intended for use in acute asthma attack. Avoid abrupt withdrawal. Childn. Pregnancy and lactation.
Adverse Reactions
Nervous: Headache.
GI: Nausea, vomiting, abdominal pain, dysgeusia, dyspepsia.
Resp: Cough, throat irritation, transient bronchospasm, pharyngitis, nasal congestion, rhinitis.
Ophthalmologic: Burning, irritation, stinging, conjunctivitis, eye redness, photophobia.
Inhalation/Respiratory/Ophth: B
Patient Counseling Information
Remove contact lenses prior to ophth admin and reinsert after 10-15 min.
Action
Description: Nedocromil is a pyranoquinoline dicarboxylic acid derivative, a mast- cell stabiliser. It suppresses immediate and delayed allergic reaction by inhibiting activation of eosinophils and release of inflammatory chemotactic and smooth muscle contracting mediators (e.g. histamine, leukotrienes, prostaglandin), thus reduces bronchospasm, cough and bronchial hyperreactivity, improves measurements of lung function, and provides relief from ocular itching associated w/ allergic conjunctivitis.
Pharmacokinetics:
Absorption: Approx 5 % is absorbed from the resp tract (inhalation). <4% is absorbed systemically (ophth). Time to peak plasma concentration: W/in 1 hr.
Distribution: Plasma protein binding: Approx 89%.
Excretion: Mainly via urine (70%, as unchanged drug); faeces (30%, as unchanged drug). Elimination half-life: Approx 1-3.3 hr.
Chemical Structure

Chemical Structure Image
Nedocromil

Source: National Center for Biotechnology Information. PubChem Database. Nedocromil, CID=50294, https://pubchem.ncbi.nlm.nih.gov/compound/Nedocromil (accessed on Jan. 22, 2020)

Storage
Ophth: Store below 25°C. Inhalation: Store below 30°C. Protect from direct sunlight.
ATC Classification
R03BC03 - nedocromil ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, antiallergic agents.
S01GX04 - nedocromil ; Belongs to the class of other ophthalmologic antiallergics.
References
Alocril Solution/Spray (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/10/2017.

Anon. Nedocromil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/10/2017.

Buckingham R (ed). Nedocromil Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2017.

Joint Formulary Committee. Nedocromil Sodium. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Nedocromil (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/10/2017.

Disclaimer: This information is independently developed by MIMS based on Nedocromil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in